Kinase inhibitors such as imatinib (Gleevec) have improved the outlook for many people with chronic myeloid leukemia and related blood disorders. But such drugs do not target the leukemia stem cell population and may not be curative. Krause and Van Etten discuss several clinical studies that suggest that interferon-α may provide a solution by selectively eliminating leukemic stem cells—although only more basic research will tell us whether this is true and how it may happen.
References
Van Etten, R.A. & Shannon, K.M. Cancer Cell 6, 547–552 (2004).
Kiladjian, J.J. et al. Blood 108, 2037–2040 (2006).
Quintás-Cardama, A. et al. Blood (ASH Annual Meeting Abstracts) 110, 3542 (2007).
Rousselot, P. et al. Blood 109, 58–60 (2007).
Alimena, G. et al. Leuk. Res. 32, 255–261 (2008).
Kantarjian, H.M. et al. Cancer 97, 1033–1041 (2003).
Silver, R.T. Cancer 107, 451–458 (2006).
Druker, B.J. et al. N. Engl. J. Med. 355, 2408–2417 (2006).
Krause, D.S. & Van Etten, R.A. Trends Mol. Med. 13, 470–481 (2007).
James, C., Ugo, V., Casadevall, N., Constantinescu, S.N. & Vainchenker, W.A. Trends Mol. Med. 11, 546–554 (2005).
Michor, F. et al. Nature 435, 1267–1270 (2005).
Schmidt, M., Hochhaus, A., Nitsche, A., Hehlmann, R. & Neubauer, A. Blood 97, 3648–3650 (2001).
Pane, F. et al. Blood 94, 2200–2207 (1999).
Angstreich, G.R. et al. Br. J. Haematol. 130, 373–381 (2005).
Copland, M., Fraser, A.R., Harrison, S.J. & Holyoake, T.L. Cancer Immunol. Immunother. 54, 297–306 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krause, D., Van Etten, R. Interfering with leukemic stem cells. Nat Med 14, 494–495 (2008). https://doi.org/10.1038/nm0508-494
Issue Date:
DOI: https://doi.org/10.1038/nm0508-494
- Springer Nature America, Inc.
This article is cited by
-
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia
Leukemia (2010)
-
IFN-α wakes up sleeping hematopoietic stem cells
Nature Medicine (2009)